- Home
- ADSE vs ATXS Comparison
ADSE vs ATXS Comparison
Compare ADSE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- ATXS
- Stock Information
- Founded
- ADSE 1980
- ATXS 2008
- Country
- ADSE Ireland
- ATXS United States
- Employees
- ADSE N/A
- ATXS N/A
- Industry
- ADSE Industrial Specialties
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ADSE Consumer Discretionary
- ATXS Health Care
- Exchange
- ADSE Nasdaq
- ATXS Nasdaq
- Market Cap
- ADSE 713.5M
- ATXS 401.2M
- IPO Year
- ADSE N/A
- ATXS 2015
- Fundamental
- Price
- ADSE $11.14
- ATXS $6.38
- Analyst Decision
- ADSE
- ATXS Strong Buy
- Analyst Count
- ADSE 0
- ATXS 7
- Target Price
- ADSE N/A
- ATXS $32.43
- AVG Volume (30 Days)
- ADSE 87.9K
- ATXS 359.8K
- Earning Date
- ADSE 05-12-2025
- ATXS 08-11-2025
- Dividend Yield
- ADSE N/A
- ATXS N/A
- EPS Growth
- ADSE N/A
- ATXS N/A
- EPS
- ADSE N/A
- ATXS N/A
- Revenue
- ADSE $113,896,884.00
- ATXS N/A
- Revenue This Year
- ADSE $219.58
- ATXS N/A
- Revenue Next Year
- ADSE N/A
- ATXS N/A
- P/E Ratio
- ADSE N/A
- ATXS N/A
- Revenue Growth
- ADSE 2.45
- ATXS N/A
- 52 Week Low
- ADSE $9.00
- ATXS $3.56
- 52 Week High
- ADSE $16.35
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- ADSE 42.13
- ATXS 71.44
- Support Level
- ADSE $11.00
- ATXS $5.60
- Resistance Level
- ADSE $13.90
- ATXS $6.89
- Average True Range (ATR)
- ADSE 0.93
- ATXS 0.35
- MACD
- ADSE -0.17
- ATXS 0.09
- Stochastic Oscillator
- ADSE 10.14
- ATXS 94.51
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.